Genzyme kept by Bear Stearns at outperform

Genzyme Inc. was maintained by Bear Stearns analyst Mark Schoenebaum at an outperform rating with a price target on the stock of $78 per share. Bear Stearns noted that the Medicare Part D formularies are due any day and a favorable placement could boost Genzyme's Renagel sales in 2006. Genzyme shares Monday were up $0.87, or 1.25%, at $70.39 on volume of 1,921,274 shares versus the three-month running average of 2,703,860 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.